M.A. Gentil
- Transplantation top 0.5%
- Renal Transplantation Outcomes and Treatments 36
- Hepatology top 5%
- Hepatitis C virus research 9
- Nephrology top 5%
- Dialysis and Renal Disease Management 6
- Epidemiology top 10%
- Cytomegalovirus and herpesvirus research 7
- Herpesvirus Infections and Treatments 6
- Psychiatry and Mental health top 10%
- Neurological Complications and Syndromes 13
-
- Pharmacological Effects and Toxicity Studies 10
-
- Organ Donation and Transplantation 6
M.A. Gentil
58 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 70
- Transplantation 702
- Hepatology 257
- Nephrology 214
- Epidemiology 442
- Psychiatry and Mental health 173
Countries citing papers authored by M.A. Gentil
This map shows the geographic impact of M.A. Gentil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.A. Gentil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.A. Gentil more than expected).
Fields of papers citing papers by M.A. Gentil
This network shows the impact of papers produced by M.A. Gentil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.A. Gentil. The network helps show where M.A. Gentil may publish in the future.
Co-authorship network
The 25 scholars most cited alongside M.A. Gentil, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 18 | |
| 2 | 2016 | 17 | |
| 3 | 2015 | 13 | |
| 4 | 2013 | 10 | |
| 5 | 2010 | 13 | |
| 6 | 2010 | 28 | |
| 7 | 2009 | 21 | |
| 8 | 2009 | 47 | |
| 9 | 2008 | 9 | |
| 10 | 2008 | 26 | |
| 11 | Pharmacokinetics of total and free mycophenolic acid in renal transplantation receiving standard-dose cyclosporine, low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: The symphony PK sub-study | 2007 | 4 |
| 12 | 2005 | 8 | |
| 13 | 2005 | 2 | |
| 14 | 2004 | 7 | |
| 15 | 2004 | 16 | |
| 16 | 2004 | 38 | |
| 17 | 2003 | 13 | |
| 18 | 2003 | 7 | |
| 19 | 2002 | 13 | |
| 20 | 1998 | 1 |
About M.A. Gentil
M.A. Gentil is a scholar working on Transplantation, Nephrology and Hepatology, having authored 59 papers that have together received 1.3k indexed citations. Recurring topics across this work include Renal Transplantation Outcomes and Treatments (36 papers), Neurological Complications and Syndromes (13 papers), Pharmacological Effects and Toxicity Studies (10 papers), Hepatitis C virus research (9 papers), Cytomegalovirus and herpesvirus research (7 papers), Organ Donation and Transplantation (6 papers), Dialysis and Renal Disease Management (6 papers) and Herpesvirus Infections and Treatments (6 papers). The work is most often cited by research in Transplantation (702 citations), Hepatology (257 citations) and Nephrology (214 citations). M.A. Gentil has collaborated with scholars based in Spain, Sweden and Belgium. Frequent co-authors include Virginia Cabello, Elisa Cordero, José Miguel Cisneros, Gabriel Bernal, Julia Fijo, P. Pereira, G. Algarra, Béatriz Valéra, F.M. González-Roncero and Henrik Ekberg. Their work appears in journals such as Nephrology Dialysis Transplantation, Transplantation, Transplant International, Clinical Kidney Journal and Journal of Infection.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.